LPS (E. coli O55:B5 strain) (VAdv-Ly0082)
| CAT | Size | Price | Quantity | |
|---|---|---|---|---|
| VAdv-Ly0082 |
|
Lipopolysaccharide from E. coli O55:B5 strain, a TLR4-based adjuvant.
Datasheet
Specifications
Type
Lipopolysaccharide
Specificity
TLR4 agonist
Product Form
Powder
Endotoxin
Less than 0.2%.
Adjuvant Information
Introduction
Lipopolysaccharide (LPS) is a natural adjuvant synthesized by gram-negative bacteria and is a potent activator of the immune system. LPS stimulates the immune response through TLR4. LPS drives Th1 immunity, although in certain circumstances low-dose inhaled LPS can promote Th2 responses. While LPS is a potent adjuvant, its pyrogenic activity has prevented clinical use of LPS in vaccines.
Related Product
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
